Secondary prevention in coronary heart disease patients with low HDL: Which options do we have?

International Journal of Cardiology

Volumn 90, Issue 1, 2003, Pages 15-21

  Liem, A H ^a   Jukema, J W ^b   Van Veldhuisen, D J ^c  

^a Oosterschelde Ziekenhuizen ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cholesterol; Coronary artery disease; HDL; Secondary prevention

Indexed keywords

BEZAFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET; DRUG EFFECT; DRUG EFFICACY; EXERCISE; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SMOKING CESSATION; WEIGHT REDUCTION;

EID: 0038719673     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00515-6     Document Type: Review

References (27)

1. Shah P.K., Kaul S., Nilsson J., Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 104:2001;2376-2383.
2. Tall A.R., Jiang X., Luo Y., et al. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol. 20:2000;1185-1188.
3. Gordon T., Castelli W.P., Hjortland M.C., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 62:1977;707-714.
4. Miller G.J., Miller N.E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1:1975;16-19.
5. Rubins H.B., Robins S.J., Collins D., et al. Distribution of lipids in 8500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 75:1995;1196-1201.
6. Rubins H.B., Robins S.J., Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group. Am J Cardiol. 78:1996;572-575.
7. Marcil M., Brooks-Wilson A., Clee S.M., et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 354:1999;1341-1346.
8. Pfeffer M.A., Sacks F.M., Moye L.A., et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. Cholesterol And Recurrent Events. J Am Coll Cardiol. 33:1999;125-130.
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
10. Ballantyne C.M., Olsson A.G., Cook T.J., et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:2001;3046-3051.
11. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatine in 20 536 high-risk individuals: a randomized placebo controlled trial. Lancet. 360:2002;7-22.
12. Ericsson C.G. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Eur Heart J. 19:(suppl. H):1998;H37-H41.
13. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 357:2001;905-910.
14. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 341:1999;410-418.
15. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events; VA-HIT: a randomized controlled trial. J Am Med Assoc. 285:2001;1585-1591.
16. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 102:2000;21-27.
17. van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., Der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 20:2000;2408-2413.
18. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatine in ischemic disease (LIPID) trial. Circulation. 105:2002;1162-1169.
19. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 358:2001;2026-2033.
20. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother. 35:2001;908-917.
21. Kastelein J.J., Isaacsohn J.L., Ose L., et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 86:2000;221-223.
22. Crouse J.R. III, Frohlich J., Ose L., et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 83:1999;1476-1477.
23. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 355:2000;253-259.
24. de Grooth G.J., Kuivenhoven J.A., Stalenhoef A.F.H., et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. Circulation. 105:2002;2159-2165.
25. Navab M., Anantharamaiah G.M., Hama S., et al. Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105:2002;290-292.
26. Spieker L.E., Sudano I., Hürlimann D., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 105:2002;1399-1402.
27. Milano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation. 97:1998;780-785.